NeoDynamics AB (publ) is a Swedish Medical Technology Company dedicated to advancing diagnosis and care of breast cancer. The company has an innovative biopsy system, NeoNavia, in late stage development. 

The precision biopsy system is built on a patented micro-pulse technology, based on research at the Karolinska Institutet in Sweden. It is designed to offer clinicians and patients accurate lesion targeting and high tissue yield for correct diagnosis and individualized treatment. NeoNavia is evaluated at leading clinics in UK, Germany and Sweden. A commercial launch is expected in 2020.

We at Neodynamics want to contribute to better diagnostic methods for the millions of women in the world who suffer from breast cancer each year, thereby increasing the chances of survival.

Anna Eriksrud, CEO of NeoDynamics